Mindset Pharma Inc.

Recent News

  • Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio

    Toronto, Ontario--(Newsfile Corp. - April 20, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce, that based on data derived from Mindset's in vivo testing program (i.e. testing in animal subjects) carried out by InterVivo Solutions Inc., the Company has confirmed that the majority of its patent pending compounds across four families of chemical scaffolds are exhibiting favourable effects in vivo in models established as having a high correlation to...

    2021-04-20 7:00 AM EDT
  • Mindset Pharma Announces Exercise of Over-Allotment Option for Additional Gross Proceeds of $1.052 Million

    Toronto, Ontario--(Newsfile Corp. - April 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that in connection with its previously announced "bought deal" public offering (the "Offering") underwritten by Canaccord Genuity Corp. (the "Lead Underwriter"), as lead underwriter and sole bookrunner, along with Stifel Nicolaus Canada Inc. and Cormark Securities Inc. (collectively with the Lead Underwriter, the "Underwriters"), the Underwriters have partially exercised their over-allotment option (the "Over-Allotment Option"),...

    2021-04-19 9:36 AM EDT
  • Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering

    Toronto, Ontario--(Newsfile Corp. - April 15, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has completed the previously announced "bought deal" public offering through the issuance of an aggregate of 10,000,000 units (each, a "Unit") of the Company at a price of $0.75 per Unit (the "Issue Price") for aggregate gross proceeds to the Company of $7,500,000 (the "Offering"). The Units were issued and sold pursuant to...

    2021-04-15 9:10 AM EDT
  • Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020

    Toronto, Ontario--(Newsfile Corp. - April 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) ("Mindset" or the "Company") - Mindset announces that it has refiled its interim financial statements for the three and six month period ended December 31, 2020 (the "Financial Statements") and accompanying management discussion and analysis (the "MD&A") as they have been restated to reflect certain adjustments resulting from a review by the Company's auditors.The following adjustments were made to the restated unaudited interim...

    2021-04-01 10:28 PM EDT
  • Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

    Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appointment of Dr. Malik Slassi as Senior Vice President of Innovation in a full time capacity and the appointment of Mr. Ian Dean as Director...

    2021-03-30 7:00 AM EDT
  • Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set

    Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that it has entered a co-development agreement with InterVivo Solutions Inc. ("InterVivo" or "IVS"), to co-develop a new translational testing platform that Mindset and InterVivo expect will introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines...

    2021-03-23 8:59 AM EDT
  • Mindset Pharma Announces DTC Eligibility for OTCQB(R) Venture Listing

    Toronto, Ontario--(Newsfile Corp. - March 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has received confirmation of eligibility from The Depository Trust Company ("DTC") for electronic settlement and transfer of its common shares in the United States. The Company's common shares are currently listed and posted for trading on the...

    2021-03-17 7:00 AM EDT
  • Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs

    Toronto, Ontario--(Newsfile Corp. - March 15, 2021) -  Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has filed a sixth provisional patent application with the United States Patent and Trademark Office. This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine ("DMT") and 5-methoxy-N,N-dimethyltryptamine ("5-MeO-DMT") analogs, their related chemical process synthesis, composition of matter and therapeutic uses. Both 5-MeO-DMT and DMT possess unique pharmacodynamic and pharmacokinetic properties compared to other...

    2021-03-15 7:00 AM EDT